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Abstract: Systemic sclerosis (SSc, scleroderma) is an autoimmune disease characterized by widespread vascular
injury and progressive fibrosis of the skin and internal organs. SSc-related involvement of the lungs, heart,
kidneys and/or the gastrointestinal system accounts for the increased mortality of scleroderma patients. Despite
the progress which has recently been made in this field, the treatment of SSc is still unsatisfactory due to the low
efficacy and/or high toxicity of available therapies. Leukotrienes are a family of lipid mediators synthesized from
arachidonic acid in a process mediated by 5-lipoxygenase; they include leukotriene B4 and a group of cysteinyl
leukotrienes: C4, D4, and E4. Leukotrienes play an important role in the regulation of all the processes vital to
the pathogenesis of SSc, namely inflammation, vascular function and connective tissue remodeling. The avail-
able data suggests that an excessive synthesis of leukotrienes may contribute to the development and progres-
sion of SSc. Accordingly, blockade of leukotriene pathways appears to be a new, promising target for the treat-
ment of SSc. (Folia Histochemica et Cytobiologica 2012, Vol. 50, No. 2, 180–185)
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Introduction
Systemic sclerosis (SSc, scleroderma) is an autoim-
mune disease involving the skin, musculoskeletal sys-
tem, lungs, heart, gastrointestinal tract and kidneys.
The involvement of internal organs results in in-
creased mortality of patients with SSc. In particular,
pulmonary complications such as SSc-related inter-
stitial lung disease (SSc-ILD, pulmonary fibrosis) and
pulmonary hypertension are currently the leading
causes of disease-related deaths [1, 2].
There are no universal disease-modifying treat-
ments available in SSc. Despite the progress that has
recently been made in the management of specific
SSc-related organ involvement, the efficacy of SSc
treatment remains unsatisfactory [3]. Moreover, the
toxicity of available drugs is still significant, mean-
ing that new potent therapeutic targets are being
sought [4, 5].
The etiology of SSc is unknown and its pathogen-
esis not fully understood. Although excessive fibrosis
is the most characteristic pathological feature of SSc,
it is considered to be a late and irreversible stage of
the disease. In addition to fibrosis, vascular injury and
tissue inflammation are considered to be important
contributors to SSc pathology.
Leukotrienes — definition and synthesis
Leukotrienes represent a group of lipid mediators
synthesized from arachidonic acid in a process medi-
ated by 5-lipoxygenase (5-LOX). The group of leu-
kotrienes includes leukotriene A4 (LTA4), a short-
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-living intermediate product of the leukotriene syn-
thesis pathway, leukotriene B4 (LTB4), and the group
of cysteinyl leukotrienes: C4 (LTC4), D4 (LTD4), and
E4 (LTE4).
Cysteinyl leukotrienes belong to the group of pro-
inflammatory mediators and are referred to as slow
reacting substances of anaphylaxis [6, 7]. Leukotrienes
were discovered in animal lungs during provocation
challenges with snake’s venom, the main enzymatic
component of which is phospholipase A2. Stimula-
tion with immunological, allergic, or inflammatory
factors initiates the synthesis of leukotrienes from
phospholipids as a result of the release of intracellu-
lar Ca2+ ions that subsequently induce translocation
of cytosolic phospholipase A2 alpha and 5-LOX into
the endosomal structures of the cell [8].
The synthesis of leukotrienes requires the pres-
ence of 5-lipoxygenase activating protein (ALOX5AP/
/FLAP). The ALOX5AP/FLAP protein is thought to
participate in selective translocation of arachidonic
acid to 5-LOX, which catalyzes its oxygenation to
5-hydroperoxyeicosatetraenoic acid (5-HpETE) and
a further dehydration of the latter to the unstable leu-
kotriene LTA4. As a result of hydrolysis, LTA4 is trans-
formed into pro-inflammatory LTB4, a chemotactic
factor and leukocyte activator — Figure 1 [8, 9].
In another metabolic pathway, LTA4 is bound to
glutathione by LTC4 synthase leading to the genera-
tion of leukotrienes containing a cysteinyl group:
LTC4, LTD4, and LTE4 [8].
Leukocytes constitute the principal source of leu-
kotrienes and the profile of the latter depends on the
type of white blood cell. Neutrophils produce mainly
LTB4, eosinophils and basophils synthesize cysteinyl
leukotrienes, while monocytes/macrophages can gen-
erate both groups of leukotrienes. Additionally, oth-
er cells (fibroblasts, epithelial cells, blood platelets)
have been shown to be able to synthesize leukotrienes,
but to a lesser extent [6].
Biological function of leukotrienes
Leukotrienes act via the activation of cell-surface pro-
tein G-bound receptors. Depending on the type of
G protein, receptors transmit the signal by changing
the intracellular cAMP, calcium, or diacylglycerol levels.
Leukotriene LTB4 acts via BLT1 and BLT2 receptors,
while cysteinyl leukotrienes activate CysLT1 and
CysLT2 receptors. Leukotrienes are considered to be
pro-inflammatory mediators [reviewed in more de-
tail in refs. 8 and 9]. Leukotriene LTB4 is one of the
strongest neutrophil chemoattractants and activators.
Through the activation of NFkB factor and AP1, LTB4
stimulates the synthesis of various pro-inflammatory
cytokines, including tumor necrosis factor alpha
(TNFa), interleukin 6 (IL-6), interleukin 8 (IL-8),
and fibroblast growth factor (FGF) [8]. Leukotriene
LTB4 activates monocytes/macrophages to synthesize
and release mediators responsible for the aggrega-
tion of other immune cells, i.e. T lymphocytes, in the
area involved in the inflammatory process. Activated
T lymphocytes can, in turn, induce enhanced expres-
sion of ALOX5AP/FLAP protein in macrophages,
leading to the intensified synthesis of leukotriene
LTB4 [9]. These processes produce a positive feed-
back loop which plays a role in amplification of the
inflammatory response. Novel anti-leukotriene ther-
apies may reveal their anti-inflammatory properties
by interrupting this ‘vicious circle’.
Leukotrienes have been shown to modulate the
function of blood vessels [9–11]. Cysteinyl leukotrienes
powerfully contract bronchial and vascular smooth
muscles, increase the permeability of blood vessels, and
activate endothelial cells [9, 11]. Furthermore, leuko-
trienes are involved in the proliferation and migration
of vascular smooth muscle cells [9, 10]. It has recently
been shown that the role of leukotrienes in vascular
biology is more complex, and vasomotor response to
leukotrienes depends on the functional status of vas-
cular endothelium as well as on the expression of
a given subtype of leukotriene receptor. Accordingly,
activation of CysLT2 receptors on endothelial cells can
lead to the synthesis of nitric oxide (NO), a powerful
vasodilatory and anti-proliferative mediator, while
stimulation of endothelial CysLT1 receptor may in
contrast result in the release of contractile factors [re-
viewed in ref. 9]. In some pathologic conditions, LTB4
can affect endothelial cell biology in yet another way.
The complex of LTB4 with proteins has been shown
to be responsible for cytotoxic effects directed against
the endothelial cells in SSc patients [12].
Figure 1. Leukotriene synthesis pathway
5-LOX — 5-lipoxygenase; 5-HETE — 5-hydroperoxyeicosatetraenoic acid;
ALOX5AP/FLAP — 5-lipoxygenase activating protein; LTA4 — leukotriene
A4; LTB4 — leukotriene B4; LTC4 — leukotriene C4; LTD4 — leukotriene
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Leukotrienes have also been shown to be involved
in the regulation of fibroblast function and connective
tissue remodeling [13]. Leukotriene LTB4 stimulates
the migration of fibroblasts. Cysteinyl leukotrienes in-
duce synthesis of collagen, differentiation of fibroblasts
into myofibroblasts, and stimulate epithelial cells to
synthesize transforming growth factor beta (TGF-
-beta), which plays a pivotal role in the processes of
fibrosis [13]. Moreover, leukotrienes may contribute
to the regulation of synthesis, secretion, and activation
of matrix metalloproteinases (MMPs) which play a key
role in the remodeling of connective tissue [14]. It has
been shown that 5-LOX and MMPs are co-expressed
in the atherosclerotic lesions of the carotid artery [15].
Leukotrienes and systemic sclerosis
Leukotrienes play an important role in the regula-
tion of all the processes vital to the development of
SSc, namely inflammatory response, blood vessel
function and connective tissue synthesis. According-
ly, both the results of human studies and the experi-
mental data suggest that an impaired balance between
various classes of eicosanoids, and particularly exces-
sive synthesis of leukotrienes, may be of key impor-
tance to the SSc pathogenesis.
It has been shown that 5-LOX, a key enzyme in
leukotriene biosynthesis, is overexpressed in the skin
of patients with SSc compared to healthy controls [16].
Expression of 5-LOX has been mainly found in mono-
nuclear cells within perivascular inflammatory infil-
trates, but also in fibroblast-like cells throughout the
skin. In vitro studies have revealed that skin fibroblast
from both SSc patients and healthy subjects express
5-LOX and synthesize leukotrienes, with fibroblast
from SSc patients producing significantly greater
amounts of LTB4 compared to cells derived from
healthy subjects. Despite a significantly higher syn-
thesis of LTB4, no significant difference in the level
of expression of 5-LOX between SSc fibroblasts and
cells derived from healthy controls has been revealed.
Recently, however Xiao et al. showed that in cultured
fibroblasts from early (of less than two years’ dura-
tion) diffuse SSc patients, the expression of 5-LOX
was significantly greater than in normal human der-
mal fibroblasts [17]. The discrepancies between the
two above-mentioned studies regarding expression of
5-LOX in SSc fibroblasts could potentially be ex-
plained by the heterogeneity of fibroblasts derived
from patients with SSc, with cells taken from early
diffuse SSc being most active [18]. Indeed, the rele-
vance of overexpression of 5-LOX in pro-fibrotic ac-
tivities of SSc fibroblast seems to be further confirmed
by the results of Xiao and al. who showed that inhibi-
tion of 5-LOX with MK886, a specific 5-LOX inhibi-
tor, was associated with decreased expression of col-
lagen types I and III as well as two cytokines consid-
ered to be of key importance for SSc pathogenesis:
transforming growth factor beta1 (TGFbeta1) and
connective tissue growth factor (CTGF) [17].
Human studies indicate that increased synthesis
of leukotrienes (activation of the leukotriene path-
way) might also play an important role in the devel-
opment of scleroderma-related interstitial lung dis-
ease (SSc-ILD) [reviewed in more detail in ref. 19].
High concentrations of LTB4 and LTE4 were found
in the lungs of patients with SSc-ILD compared to
SSc patients without SSc-ILD and healthy controls
[20, 21]. Concentrations of LTB4 and LTE4 had a sig-
nificantly positive correlation with each other and with
the fraction of inflammatory cells in bronchoalveolar
lavage fluid (BALF). The concentration of leukot-
riene LTB4 correlated positively with the percentage
of neutrophils, which is considered a marker of local
inflammation in the lower respiratory tract and a poor
prognostic factor [20, 22]. Moreover, concentrations
of both LTB4 and LTE4 in the BALF negatively cor-
related with FVC [20]. These findings are in agree-
ment with the study of Wilborn et al. who showed
that tissue homogenates obtained from patients with
idiopathic pulmonary fibrosis (IPF), a prototypic fi-
brotic lung disease, contained 15-fold higher concen-
trations of LTB4, and five-fold higher levels of LTC4,
compared to control samples of nonfibrotic lung tis-
sue [23]. The concentration of LTB4 in the homoge-
nates of fibrotic lungs strongly correlated with histo-
pathological indices of inflammation and fibrosis.
Moreover, elevated leukotriene concentrations have
also been observed in lung fibrosis associated with
pigeon breeder’s lung [24].
Recently, Tufvesson et al. measured the concen-
tration of leukotrienes in exhaled breath condensates
of 22 patients with SSc, including 12 patients with SSc-
ILD as defined by the presence of traction bron-
chiectasis within areas of ground-glass opacities and/
/or reticulation in high resolution computed tomogra-
phy (HRCT) of the lungs [25]. They showed that con-
centration of cysteinyl leukotrienes is significantly
higher in exhaled breath condensates of SSc patients
compared to healthy controls. Although the concen-
tration of LTB4 significantly correlated with the con-
centration of cysteinyl leukotrienes, the difference in
LTB4 levels was not significant between SSc patients
and the control group. No association was document-
ed in this group between the leukotriene concentra-
tions and radiological findings of HRCT or function-
al pulmonary tests [25]. There is no ready explana-
tion for the discrepancies between measurements of
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LTB4 in BALF and exhaled breath condensates; how-
ever, it could be due to the limited numbers of pa-
tients with SSc-ILD in the study by Tufvesson and/or
the influence of treatment which could potentially
alter leukotriene metabolism. Indeed, in the study by
Tufvesson several patients received non-steroidal anti-
inflammatory drugs or steroids. These observations
are of particular interest in view of our previous re-
sults showing that immunosuppressive treatment of
SSc-ILD resulted in a significant decrease in the con-
centration of LTB4, but had no effect on LTE4, in
the lungs of patients with SSc-ILD [20].
The exact source of increased synthesis of leukot-
rienes in the lungs of patients with SSc-ILD has not
been identified. Immunohistochemical studies in id-
iopathic pulmonary fibrosis have shown that 5-LOX
is expressed mainly in alveolar macrophages in both
patients with pulmonary fibrosis and the control sam-
ples of nonfibrotic lung tissue from patients under-
going resectional surgery for bronchogenic carcino-
ma [23]. In vitro, alveolar macrophages from patients
with idiopathic pulmonary fibrosis synthesized signif-
icantly greater amounts of LTB4 and LTC4 compared
to cells obtained from normal subjects [23]. It can also
be supposed that neutrophils, which are known to be
increased in the lungs of patients with pulmonary fi-
brosis and are able to synthesize LTB4, could be an
additional source of leukotrienes in the lungs of pa-
tients with SSc-ILD. Studies performed in SSc re-
vealed that neutrophils and mononuclear cells from
the peripheral blood of SSc patients synthesize high-
er amounts of leukotrienes than cells obtained from
healthy individuals [26, 27]. In SSc patients, higher
levels of LTB4 in the peripheral blood mononuclear
cells (PBMC) cultures were associated with more se-
vere disease as indicated by the presence of diffuse
skin involvement, restrictive SSc-ILD, pulmonary
hypertension, and greater vascular injury in capillaros-
copy [28]. Moreover, higher concentrations of leu-
kotrienes in PBMC cultures were associated with sub-
sequent progression of the disease.
Recent studies indicate that leukotrienes may pro-
mote fibrosis and contribute to vascular diseases by
the activation of platelets, which are a rich source of
growth factors. Thrombocytes contain cysteine leukot-
riene receptors, and platelet activation markers have
been demonstrated in BALF of SSc patients [29, 30].
Arterial pulmonary hypertension is another severe
complication of SSc and one of the major causes of
mortality in SSc [1, 2]. Histologically, pulmonary ar-
terial hypertension is characterized by the prolifera-
tion of vascular tunica intima, hypertrophy of tunica
media, and fibrosis of pulmonary vessels. No studies
investigating leukotriene pathways specifically in SSc-
-related pulmonary arterial hypertension have been
identified so far. However, Wright et al. reported that
5-LOX and ALOX5AP/FLAP are overexpressed in
the lungs of patients with primary pulmonary hyper-
tension, indicating that the leukotriene pathway might
be involved in the pathogenesis of this disease. In
patients with idiopathic arterial hypertension, the
number of 5-LOX positive macrophages was higher
and the intensity of staining for 5-LOX and
ALOX5AP/FLAP in small pulmonary arteries was
greater compared to normal subjects and patients with
intestinal lung disease [31].
The results of experiments using animal models
further support the significant role of leukotrienes in
the pathogenesis of SSc-related organ complications.
Moreover, the results of these experiments indicate
that inhibition of leukotriene pathways might be of
potential therapeutic benefit in the treatment of the
most severe SSc-related organ involvement such as
SSc-ILD and/or pulmonary hypertension.
It has been shown that the concentration of leu-
kotrienes is increased in the lungs of mice with bleo-
mycine-induced lung fibrosis [32]. It has also been
shown that mice deficient in 5-LOX, a key enzyme in
leukotriene biosynthesis, were protected against ble-
omycine-induced lung fibrosis compared to wild mice
showing normal expression of 5-LOX [32]. A protec-
tive effect was also observed after the administration
of a 5-LOX inhibitor (zileuton) [33]. Moreover, it has
been shown the LTB4 receptor antagonist diminish-
es the development of bleomycin-induced pulmonary
fibrosis in mice by decreasing inflammation, hydrox-
yproline content and expression of TGF-beta, IL-6,
and IL-13 in the lungs [34].
The present findings concerning receptor block-
ade of the cysteinyl leukotrienes pathway in the patho-
genesis of lung fibrosis are inconsistent. Beller et al.
have shown that mice lacking CysLT2 receptor were
protected against bleomycin-induced pulmonary fi-
brosis, while genetic disruption of CysLT1 receptor
led to worse fibrotic response in the lungs of animals
challenged with bleomycin [35, 36]. On the other
hand, Izumo et al. showed that montelukast, which is
a CysLT1 receptor antagonist, inhibits the inflamma-
tory process and development of bleomycin-induced
pulmonary fibrosis in mice, and these effects may be
associated with a decrease in TGF-beta expression
[37]. Studies in asthma have also suggested an im-
portant role for the CysLT1 receptor in the develop-
ment of airway remodeling, which is characterized by
proliferation of the bronchial smooth muscles and
deposition of extracellular matrix proteins in the bron-
chial wall. It has been shown that administration of
CysLT1 receptor antagonist inhibited new, and re-
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versed existing, bronchial tree remodeling in a mouse
model of chronic allergic asthma [38]. Moreover, an-
tagonists of CysLT1 receptor reduced myofibroblast
deposition in the airway wall of patients subjected to
allergic provocation [39].
There is growing evidence of the role of leuko-
trienes in the pathogenesis of different types of vas-
cular diseases associated with arterial wall hypertro-
phy and ischemia-related injury, which are also im-
portant elements of SSc-related pathology. It has been
shown that overexpression of 5-LOX markedly accel-
erated the progression of pulmonary hypertension in
rats treated with monocrotaline [40]. The adminis-
tration of 5-LOX inhibitors, zileuton or MK-886, pre-
vented the development of pulmonary hypertension.
It has also been shown that inhibition of FLAP re-
duced pulmonary vascular reactivity in vitro and the
development of pulmonary hypertension in hypoxic
rats [41]. Moreover, the antagonists of CysLT1 recep-
tor were found to inhibit the hyperplasia of tunica
intima resulting from vascular injury in various ani-
mal models [10].
The role of leukotrienes in the development of
ischemia-related injury has been investigated quite
extensively, although the results of these studies gave
inconsistent results. Inhibition of leukotriene synthe-
sis has been shown to improve coronary blood flow
in isolated rabbit hearts and to diminish myocardial
injury in in vivo models of cardiac infarct in rabbits
and dogs [42, 43]. Accordingly, cysteinyl leukotriene
receptor antagonists reduced ischemia/reperfusion-
related injury of the heart in ex vivo and in vivo ani-
mal models [44, 45] and attenuated the brain injury
resulting from both transient and permanent occlu-
sion of cerebral arteries in rats [46, 47]. However, oth-
er studies did not reveal protective effects of the cys-
teinyl leukotriene or LTB4 receptors antagonists or
inhibition of leukotriene synthesis on myocardial inf-
arction area in dogs or rats [48–51]. It cannot be ex-
cluded that the differences in the above studies might
be, at least in part, due to different methods/com-
pounds used to block leukotriene pathways. A recent
study of transgenic mice overexpressing human
CysLT2 receptor in the vascular endothelium revealed
that activation of that receptor is associated with
a higher expression of inflammatory genes, a larger
area of myocardial infarction, and greater dysfunc-
tion of the heart, indicating that endothelial CysLT2
receptor is involved in the development of ischemia/
/reperfusion injury [52].
In summary, all the studies reviewed so far indi-
cate that leukotrienes are involved in the pathogene-
sis of SSc through perpetuation of inflammatory pro-
cesses, direct or indirect activation of fibroblast, and
contribution to vascular injury and remodeling. In-
creased expression of 5-LOX and/or FLAP, as well as
enhanced synthesis of leukotrienes, have been ob-
served in SSc and other conditions of similar patho-
genesis (e.g. primary pulmonary hypertension and
lung fibrosis), further supporting a key role of the leu-
kotriene pathway in the development of SSc-related
organ injury. Moreover, experimental data suggests
that inhibition of leukotriene pathways might have
a beneficial effect in SSc. This seems of particular in-
terest because an inhibitor of leukotriene synthesis
(zileuton) or CysLT receptor antagonists (e.g. mon-
telukast, zafirlukast) have been used for the treatment
of asthma and other allergic conditions. Moreover,
new anti-leukotriene therapies including LTB recep-
tor antagonists and analogs of lipoxins, natural leu-
kotriene antagonists, are under development.
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